A novel series of 4-arylaminoquinazolines were identified from a cell-based screening assay as potent apoptosis inducers.
MPC-6827: A Small-Molecule Inhibitor of Microtubule Formation That Is Not a Substrate for Multidrug Resistance Pumps Introduction
Many of the chemotherapeutic agents presently in use for cancer treatment were discovered from the screening of libraries for small molecules that inhibit the growth of neoplastic cells. Subsequently, it has been determined that many of the clinically useful cytotoxic agents primarily act by inducing apoptosis in cancer cells (1) (2) (3) . Apoptotic cell death is the consequence of a series of precisely regulated events that are frequently altered in tumor cells. Activation of caspases is a critical event for apoptosis induction (4, 5) . The sequence of events that results in the activation of caspases has been broadly categorized into two pathways: the ''extrinsic'' pathway, characterized by the engagement of cell surface ''death receptors'' (6, 7) , and the ''intrinsic'' mitochondrial mediated pathway, characterized by the release of cytochrome c from the mitochondrial intermembrane space into the cytosol (8) (9) (10) . For either pathway, the ultimate activation of caspases ensures apoptosis induction.
The principal proapoptotic chemotherapeutic agents used for both childhood and adult cancers target tubulin, including the taxanes paclitaxel and docetaxel and the Vinca alkaloids vinblastine, vincristine, and vinorelbine. Considering the clinical success of these agents, tubulin represents one of the most highly validated cancer targets identified to date (11, 12) . Tubulin targeting agents interfere with microtubule dynamics, leading to arrest of dividing cells in the G 2 -M phase of the cell cycle, which eventually results in apoptotic cell death (13) . However, emerging resistance to antimitotic agents has limited their ultimate effectiveness (14) , leading to renewed interest in the discovery and development of new agents that are active in multidrug resistant (MDR) cells and that interact with tubulin at sites different from those of the taxanes and Vinca alkaloids (15) . This field has exploded in the last few years, leading to the discovery of a variety of new smallmolecule inhibitors, which have shown promising antitumor activity even in tumors expressing MDR phenotypes with the most advance being the macrolide epothilones (16, 17) . MPC-6827 has displayed significant activity in inhibiting the growth of multiple tumor lines in athymic nude mice, which include human breast (MCF-7, MX-1, and MB-MDA-435), colon (HT-29), pancreas (MIAPaCa-2), ovarian (OVCAR-3), and mouse melanoma (B16).
Here, we present a novel chemical class of compounds, represented by the lead compound MPC-6827, which inhibit tubulin polymerization, are not substrates for ABC MDR transporters in vitro, and display a broad spectrum of antitumor activity. Taken together, these results suggest that MPC-6827 may be effective in the treatment of multiple types of human tumors. Jurkat, NIH-3T3, T47D, 22Rv1, Du145,  A549, B16-F1, OVCAR-3, HT- . NCI/ADR-RES, MCF-7/MX, P388, and P388/ADR cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 2 mmol/L glutaMAX, 1 mmol/L sodium pyruvate, 0.1 mmol/L nonessential amino acids, and 10 mmol/L HEPES (Invitrogen). MCF-7/VP cells were cultured in DMEM high glucose supplemented with 10% fetal bovine serum, 2.5% horse serum, 2 mmol/L glutaMAX, 1 mmol/L sodium pyruvate, 0.1 mmol/L nonessential amino acids, and 10 mmol/L HEPES. All cells were grown at 37jC in a humidified 5% CO 2 atmosphere.
Materials and Methods
Caspase activation. Cells were incubated with the test compounds in 384-well plates for 24 h. Caspase-3 fluorogenic substrate N-(Ac-DEVD)-N ¶-ethoxycarbonyl-R110 (21) was then added, incubated at room temperature for 3 h, and fluorescent signal resulting from caspase activation was measured using a fluorescent plate reader (Tecan Model Spectrafluor Plus). Compounds were designated as active caspase inducers if the fluorescent signal was at least 3-fold over background, based on previous demonstration that caspase-3/caspase-7 activation would yield at least this degree of fluorogenic substrate cleavage (21) . Active compounds were subsequently confirmed at several concentrations to determine EC 50 values. EC 50 values were determined by a sigmoidal dose-response calculation (XLFit3, IDBS) and represent the concentration of compound that produces 50% the maximum observed response.
Cell cycle analysis. Human Jurkat leukemia cells were used to determine the effect of MPC-6827 on cell cycle and apoptosis. Cells were treated with various concentrations of MPC-6827 for 18 h at 37jC or treated for 3 h, washed, resuspended in growth media, and then incubated for 18 h at 37jC. In experiments done to determine the effect of caspases in cell death, cells were treated with 100 nmol/L MPC-6827 for 18 h or were pretreated with 10 Amol/L MX-1013, a pan-caspase inhibitor (21) , before addition of MPC-6827. Cells were harvested at 200 Â g and washed twice with 5 mmol/L EDTA/PBS. Cells were then resuspended in 300 AL of EDTA/PBS and 700 AL of 100% ethanol, incubated at room temperature for 1 h, and centrifuged at 200 Â g, followed by removal of supernatant. A solution containing 100 Ag/mL propidium iodide and 1 mg/mL RNase A was added to the fixed cell pellets and incubated for 1 h at room temperature. Samples were then analyzed on a flow cytometer. Flow cytometric cell cycle determinations were done on FACScalibur and data output was analyzed using Cell Quest software (Becton Dickinson). Lysates were then spun in a microcentrifuge for 10 min at maximum speed to remove nuclei. The supernatant was transferred to a new tube containing 200 AL of 2Â Tris-glycine SDS reducing sample buffer. The samples were then boiled for 5 min, and 10 AL of the boiled samples were loaded onto a 4% to 12% Tris-glycine SDS gel. The gel was subsequently stained with 1% Coomassie brilliant blue in 40% methanol/7.5% acetic acid for 2 h and then destained in several changes of 40% methanol/7.5% acetic acid. The gel was then incubated in Amplify (GE Healthcare) for 30 min at room temperature and then dried on Whatman filter paper with a gel dryer at 80jC for 2 h. The dried gel was put on Hyperfilm (GE Healthcare) in a film cassette for development at À80jC for 5 days. In vitro tubulin polymerization assay. MPC-6827 was assayed at 0.5, 5, or 50 Amol/L for effect on tubulin polymerization according to the recommended procedure of the manufacturer (Cytoskeleton, #ML113, 1 mg, MAP-rich). To 1 AL of each 100Â stock of experimental compound in a 96-well plate was added 99 AL of supplemented tubulin supernatant. Incubation was carried out at 37jC in a Molecular Devices plate reader, with absorbance readings at 340 nm every minute for 1 h. The IC 50 was the concentration found to decrease the initial rate of tubulin polymerization by 50% as calculated using Prism 3.0 software (GraphPad).
Cellular tubulin staining. A549 cells were grown overnight on 18 Â 18 mm coverslips. MPC-6827 was then added at a final concentration of 10 nmol/L for 1 or 3 h at 37jC. Coverslips were removed from media and fixed in 3.7% paraformaldehyde in RPMI 1640 for 15 min at 37jC, washed thrice in 1Â HBSS, and permeabilized with 0.1% Triton-X 100. Following three washes in 1Â HBSS, coverslips were blocked with 1Â HBSS containing 1% bovine serum albumin and 0.1% Tween 20 (blocking solution) for 1 h at room temperature. Blocked coverslips were incubated with a mouse monoclonal anti-h-tubulin antibody (clone 2-28-33; 1 Ag/mL; Sigma) in blocking solution at a dilution of 1:2,000. After washing in 1Â HBSS, goat anti-mouse immunoglobulin G (H + L) conjugated with Alexa Fluor 488 (1 Ag/mL; Molecular Probes) was added in blocking solution to a final concentration of 2 Ag/mL, which also contained Hoechst 33342 (2 Ag/mL). Immunofluorescence was analyzed on the Everest Digital Microscopy Workstation (Intelligent Imaging Innovations).
Terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay. Cells were treated with 5 nmol/L MPI-0441138 for 72 h and fragmented DNA was assessed by using the terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. In the TUNEL assay, cells were fixed in 1% paraformaldehyde, washed in PBS, and then permeabilized with 70% ethanol (ApoBrdU TUNEL Assay Kit, Molecular Probes Europe BV). Labeling reactions using Alexa Fluor 488 dye-labeled anti-bromodeoxyuridine antibodies were done according to the manufacturer's protocol (Invitrogen). The fluoresceinlabeled cells were analyzed by flow cytometry (FACScan, Becton Dickinson).
Apoptosis inducible factor and cytochrome c translocation. Cells were treated with 5 nmol/L MPI-0441138 or vehicle for 1 h and then fixed for 15 min with 4% paraformaldehyde in PBS. Cells were washed with PBS and permeabilized for 15 min with 0.1% saponin in PBS containing 1% bovine serum albumin and 0.1% sodium azide. Cells were incubated at room temperature for 1 h with either rabbit anti-cytochrome c antibody or rabbit anti-apoptosis inducible factor (AIF; Cell Signaling Technology, Inc.) at a concentration of 5.0 Ag/mL, washed twice, and then incubated with anti-rabbit immunoglobulin/FITC swine F(ab ¶) 2 secondary antibody (DakoCytomation GmbH) for 30 min. All incubations were done at room temperature. After washing, cells were analyzed by fluorescence microscopy (Olympus IX71, Olympus Optical GmbH) using a blue filter of 470 to 490 nm.
Measurement of mitochondrial membrane potential. Mitochondrial membrane potential (DW m ) was determined by staining of the cells with 5,5 ¶,6,6 ¶-tetrachloro-1,1 ¶,3,3 ¶-tetraethyl-benzimidazolylcarbicyanin iodide (JC-1). 22Rv1, MDA-MB-231, Caco-2, and Du145 cells were treated with 5 nmol/L MPI-0441138 for 12, 24, 48, or 72 h at 37jC. Cells were then incubated with BD MitoSensor reagent following the manufacturer's recommended conditions (JC-1, BD Biosciences). From each sample, 25,000 events were collected to measure fluorescence in the FL-2 channel after suitable compensation.
MDR testing. Exponentially growing MCF-7, NCI/ADR-RES, MCF-7/MX, MCF-7/VP, P388, and P388/ADR cells were seeded at 5,000 per well in a 96-well flat-bottomed microtiter plate and, 24 h later, culture medium was replaced with fresh medium and varying concentrations of test compound. Cellular viability was determined 72 h after addition of test compound by measuring intracellular ATP with the ATPLite assay system (Perkin-Elmer). All compounds were tested in quadruplicate. The effect of compounds on cell viability was calculated by comparing the ATP levels of cells exposed to test compound with those of cells exposed to vehicle. A semi-log plot of (Innovative Research of America) 48 h before the injection of cells. MX-1 tumors were passaged serially in CD1 nu/nu mice. For this study, tumors from several animals were excised. The viable portion of the tumor was cut into pieces (f30 mm 3 ) and implanted into the right lateral mammary pad of each animal using a trocar. In all the allografts and xenografts, tumors were allowed to grow to f100 mm 3 and then were placed into test groups (N = 10). The dose, route of administration, and dosing regimen for each study are indicated in Table 2 . The mice were observed daily for mortality and signs of toxicity. Tumors and body weights were measured from day 1 to the end of study with the frequency measurements determined by the rate of growth of the tumor. Tumor growth was monitored using external measurements with a caliper and tumor volumes were calculated using the formula p/6 (width 2 Â length), where width represents the smaller tumor diameter. Statistical ANOVA with unadjusted pairwise comparison was done using SAS software. These studies conformed to the recommendations set forth in the USPHS Policy on Humane Care and Use of Laboratory Animals (22) .
Results and Discussion
MPC-6827 is a potent activator of caspases in various tumor cell lines. A novel series of 4-arylaminoquinazolines were identified as potent activators of caspases in a cell-based screening assay. The initial hit compound was identified in highthroughput screening by measuring the induction of apoptosis in T47D breast cancer cells using a profluorescent substrate (21) . MPI-0441138 and MPC-6827 analogues (Fig. 1A) of the original screening hit showed activities in the low nanomolar range in the caspase activation assay (1.4 F 0.3 and 2.5 F 0.4 nmol/L, respectively). To investigate the rate and potency of cell killing, Jurkat cells were exposed to varying concentrations of MPC-6827 for 3 or 18 h. Although either 3 or 18 h of exposure showed equivalent maximal induction of cell death, MPC-6827 was apparently more potent after the longer length of exposure (Fig. 1B) . To confirm that caspase activation was required for the MPC-6827-mediated induction of cell death, we tested the effect of MX-1013 (benzyloxycarbonyl-Val-Asp-fluoromethylketone), a pan-caspase inhibitor previously described to inhibit caspase activation (23) . In the presence of both MPC-6827 and MX-1013, cell death of Jurkat cells was 11% as compared with 68% cell death in the presence of MPC-6827 alone (Fig. 1C) . Furthermore, with the addition of MX-1013, the majority of MPC-6827-treated Jurkat cells were now arrested in G 2 -M (Fig. 1C) , indicating that the cells treated with MPC-6827 underwent G 2 -M arrest before caspase activation and cell death. Taken together, these results support an apoptotic mechanism of cell killing by MPC-6827.
MPC-6827 competes with a radiolabeled and photoreactive analogue for binding to a 55-kDa protein. An azido photoaffinity analogue of MPC-6827, MPI-0441264, was synthesized, which remained potent in the caspase activation assay (data not shown). A tritiated version was also prepared and used to identify the molecular target of MPC-6827 ([ 3 H]MPI-0441264; Fig. 2A ). Autoradiography of electrophoresed lysates from Jurkat cells treated with [ 3 H]MPI-0441264 revealed a prominent band at an apparent molecular weight of 55 kDa (Fig. 2B) . To assess the specificity of the labeling by the affinity probe, Jurkat cells were pretreated with 1 Amol/L MPC-6827 before incubation with [ 3 H]MPI-0441264 and photoactivation. MPC-6827 significantly reduced the amount of photolabeled 55-kDa protein (Fig. 2B) . Similar results were obtained with two additional azido photoaffinity analogues of MPC-6827 in which the azido group was located at different positions on the molecule (not shown).
Due to the apparent molecular weight of the bound protein and the cell cycle profile of the compound treated cells, the 55-kDa bound protein was suspected to be tubulin. Therefore, compounds known to bind tubulin, such as colchicine, paclitaxel, and vinblastine, were tested for the ability to compete with the [ 3 H]MPI-0441264 labeling. As shown in Fig. 2B , the 55-kDa labeled protein was clearly competed by MPC-6827, colchicine, and paclitaxel, but not by vinblastine, suggesting the 55-kDa band was likely tubulin.
MPC-6827 disrupts tubulin polymerization in vitro, binds to the colchicine-binding site, and disrupts microtubules in intact cells. To confirm that MPC-6827 bound tubulin and altered polymerization, we evaluated its effect on tubulin polymerization in an in vitro assay. MPC-6827 was tested at 0.5, 5, and 50 Amol/L, and 5 Amol/L was sufficient to completely inhibit tubulin polymerization (Fig. 2C) . Although this potency for inhibition of tubulin polymerization seemed to be low, it is likely not inconsistent with cellular potency for apoptosis induction, considering the high concentration of tubulin in the polymerization assay.
The in vitro studies clearly showed that MPC-6827 binds to tubulin and disrupts microtubule formation. We also wanted to determine if MPC-6827 was able to inhibit microtubule formation in intact cells. Microtubule disruption was rapidly induced in human A549 non-small-cell lung carcinoma cells, treated with vehicle or 10 nmol/L MPC-6827, with marked disruption after 1 h and complete disruption by 3 h (Fig. 2D ). This microtubule disruption activity is most consistent with MPC-6827 exerting functional effects through the colchicine rather than the taxane binding site on tubulin because colchicine is known to inhibit and taxanes are known to stabilize tubulin polymerization (9) . Rather than direct competition, the ability of paclitaxel to prevent labeling of the 55-kDa protein in the cellular assay may be due to microtubule stabilization from paclitaxel treatment that can block MPC-6827 from binding to the colchicine site.
MPI-0441138-induced cell death shows multiple hallmarks of apoptosis. MPI-0441138 is a close analogue of MPC-6827 and shows similar caspase activation potency. To determine whether MPC-6827 inhibits tumor growth in vivo. The in vivo efficacy of MPC-6827 was studied in s.c. allograft and xenograft models using mouse B16 melanoma and human breast (MCF-7, MX-1, and MB-MDA-435), colon (HT-29), pancreas (MIAPaCa-2), and ovarian (OVCAR-3) tumor cell lines. After implantation into the right flank region of athymic nude mice, tumors were allowed to grow to an average volume of 100 mm 3 before beginning treatment with MPC-6827. The results of each of the allograft and xenograft studies are summarized in Table 2 and an example result from a xenograft study is shown in Fig. 4 . These data indicate that MPC-6827 was efficacious in inhibiting the growth of a broad panel of tumor types.
These studies show that MPC-6827 acts through binding the colchicine site on h-tubulin, inhibiting tubulin polymerization and leading to G 2 -M arrest and apoptosis, which is activated through the intrinsic mitochondrial pathway. MPC-6827 also showed efficacy in vitro against tumor cells overexpressing the three main ABC transporters responsible for MDR, and, therefore, MPC-6827 may prove effective against drug-resistant tumors in the clinic. Importantly, MPC-6827 displayed significant inhibition of the growth of a broad spectrum of solid tumor types in xenograft models.
Currently, the macrolide epothilones are the most advanced new tubulin targeting agents in the clinic (26) . Epothilones are chemically distinct from taxanes but bind to the same binding region on h-tubulin and exert their biological effects by stabilizing microtubules. The potential advantages of the epothilones over the taxanes are better aqueous solubility, greatly reduced affinity toward drug resistance-mediating ABC transporters, and significant activity against taxane-resistant tumor cells (27, 28) . MPC-6827 is unique from the epothilones in that it binds to the colchicine site on h-tubulin and is an inhibitor of microtubule formation. Although MPC-6827 is equally potent in cell lines regardless of ABC transporter expression, its activity in xenograft models using taxane-resistant tumor cells has yet to be determined.
MPC-6827 has recently opened a phase II clinical trial designed to determine the safety profile and the extent of its ability to improve the survival of patients with glioblastoma multiforme and melanoma that has spread to the brain. 
